Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 13;23(1):148.
doi: 10.1186/s12885-023-10567-1.

What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?

Affiliations

What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?

Rahel Stiefel et al. BMC Cancer. .

Abstract

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of tumors with a broad range of local and systemic treatment options. Still a lack of data regarding treatment sequences exists. The aim of this study was to analyse outcomes in GEP-NETs depending on stage and treatment steps and compare our treatment decisions to the latest treatment recommendations of European Society of Medical Oncology (ESMO) 2020 for GEP-NETs.

Methods: Patients were included in this retrospective single-center analysis from 2012-2016. All patients suffering from a GEP-NET, who were screened, treated or evaluated at ENETS Center in Zurich, Switzerland were included in analysis. Patients with any other diagnosis of NET were not included. We used Kaplan Meier estimator as well as Cox regression to compare survival rates between different sites of localization, grades or stages and treatment sequences.

Results: Overall, we identified 256 GEP-NETs, most in advanced stage (62%) and located in small intestine tract or pancreatic gland. Survival depended on stage, grade, primary site and duration of response for the early systemic treatment. On average patients underwent 2.6 different treatment modalities, mostly depending on stage and higher tumor grade. Surgery was performed early but also in advanced stages, usually followed by Somatostatine-Agonist modalities. In distant disease (Stage IV), we investigated a positive effect of PFS after treatment with Somatostatine Analogues (SSA) (hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.21 - 0.97; p = 0.04) and systemic treatment (HR, 0.51; 95% CI, 0.26 - 0.99; p = 0.047) if patients underwent prior surgery or endoscopic resection. Kaplan Meier distributions predict shorter OS in distant disease (Stage IV), (Figure. 1; HR, 2.06; 95% CI, 1.46 - 2.89; log-rank test, p < 0.001).

Conclusion: This retrospective analysis presents a great overview of all patients', disease and treatment characteristics of GEP-NETs at ENETS Center in Zurich, Switzerland. We illustrated survival (PFS) depending on implemented therapies. According to these findings, we formed a suggested treatment algorithm for advanced GEP-NETs, which does not differ from the latest treatment recommendation by ESMO guidelines for GEP-NETs. The results of this project may define GEP-NET patients' selection for upcoming clinical prospective studies.

Keywords: GEP-NET; Overall survival; Progression free survival; Real-life population; SSA; Treatment sequences.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Treatment sequences showed by Sankey diagram [41, 33, 34]. Notes: 12 patients without any documented treatment were excluded from treatment pattern analysis. Lines ending without declarations of treatment represent patients who were not treated any further. Multiple treatment options per patient are possible. Abbreviations: CTx, chemotherapy; ER, endoscopic resection; LDT, liver directed therapy (radiofrequency ablation [RFA], selective internal radiation therapy [SIRT], transarterial [chemo-] embolization [TA(C)E]); mTOR, mTOR-inhibitors; PRRT, peptide receptor radionucleotide therapy; RT, radiotherapy; SSA, somatostatin analogues; SX, surgery; TKI, tyrosine kinase inhibitor; WW, watchful waiting
Fig. 2
Fig. 2
Kaplan Meier curves showing OS (months) according to different stages (ENETS) at first diagnosis, log-rank test, p < 0.001. Notes: Marks indicate censored cases. Median OS over all patients was 181 months (95% CI, 106 – 256 months). Abbreviations: CI, confidence interval; ENETS, European Neuroendocrine Tumor Society; OS, overall survival
Fig. 3
Fig. 3
Kaplan Meier estimator for median OS of GEP-NET patients according to primary site [6]. Notes: We were not able to investigate median OS of gastric NET patients and patients with appendix NET, due to the fact that less than 50% of these patients died until the end of the observation period. The single patient with NET of the gallbladder was extracted from illustration due to lack of statistical power. Median OS over all patients was 181 months (95% CI, 106 – 256 months). Abbreviations: CI, confidence interval; GEP, gastroenteropancreatic; NET, neuroendocrine tumor; OS, overall survival
Fig. 4
Fig. 4
Flow chart shows suggested treatment algorithm for advanced GEP-NETs (Stage III and IV, ENETS) according to the finding in our study and recommendations of other studies [3, 11, 24, 35, 40]. Abbreviations: 5-FU, 5-Fluorouracil, ENETS, European Neuroendocrine Tumor Society; G1 – G3, grade 1 – grade 3; GEP-NETs, gastroenteropancreatic neuroendocrine tumor; NEC, neuroendocrine carcinoma; PRRT, peptide receptor radionucleotide therapy; RFA, radiofrequency ablation; SSA, somatostatin analogues

References

    1. Rossi RE, Ciafardini C, Sciola V, Conte D, Massironi S. Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms. Pancreas. 2018;47(10):1249–1255. doi: 10.1097/MPA.0000000000001184. - DOI - PubMed
    1. Kos-Kudła B, Čwikła J, Ruchała M, et al. Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide. Wspolczesna Onkol. 2017;21(2):115–122. doi: 10.5114/wo.2017.68619. - DOI - PMC - PubMed
    1. Öberg K. Neuroendocrine tumors of the digestive tract: Impact of new classifications and new agents on therapeutic approaches. Curr Opin Oncol. 2012;24(4):433–440. doi: 10.1097/CCO.0b013e328353d7ba. - DOI - PubMed
    1. Oncology P. Database Report 2015. 2016. https://www.swissnet.net/images/files/SwissNETReport2015.pdf.
    1. Kollar A, Bütikofer L, Ochsenbein A, Stettler C, Trepp R. Treatment sequence in patients with neuroendocrine tumours: a nationwide multicentre, observational analysis of the Swiss neuroendocrine tumour registry. Swiss Med Wkly. 2020;150:w20176. 10.4414/smw.2020.20176. - PubMed

Supplementary concepts